# Eli Lilly invests $400M in biomanufacturing expansion in Indianapolis

Eli Lilly will invest $400 million to expand biomanufacturing capacity at its Lilly Technology Center campus in Indianapolis, Indiana. The investment will support production of diabetes medicines, including insulins and Trulicity, with capacity and technology upgrades.

- Type: Expansion
- Announced: 2019-11-20
- Where: Indianapolis, Indiana, United States
- Value: $400.0M
- Jobs: 100
- Status: announced
- Products: insulin, Trulicity (dulaglutide), diabetes medicines
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Eli Lilly](https://endata.com/companies/32564.md)

## Sources

- [bioprocessintl.com](https://www.bioprocessintl.com/facilities-capacity/indie-400-eli-lilly-cites-tax-reform-in-latest-biomanufacturing-expansion), 2019-11-20: "These investments will enhance our existing facilities that make insulin, provide additional capacity for our growing portfolio of diabetes medicines and provide initial capacity for future medicines."
- [assemblymag.com](https://www.assemblymag.com/articles/95325-eli-lilly-to-create-100-jobs-as-it-adds-capacity-to-its-technology-center-campus), 2019-11-26: "These investments support our manufacturing capabilities in Indianapolis, including additional capacity and technology upgrades to our active ingredient, syringe filling, device assembly and packaging operations."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.